Krimo Bouabdallah

Krimo Bouabdallah

UNVERIFIED PROFILE

Are you Krimo Bouabdallah?   Register this Author

Register author
Krimo Bouabdallah

Krimo Bouabdallah

Publications by authors named "Krimo Bouabdallah"

Are you Krimo Bouabdallah?   Register this Author

55Publications

2845Reads

30Profile Views

Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?

J Nucl Med 2020 Feb 14. Epub 2020 Feb 14.

CHU Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.120.242594DOI Listing
February 2020

Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma.

J Clin Oncol 2018 07 23;36(20):2124-2125. Epub 2018 May 23.

Charles Mesguich, Krimo Bouabdallah, Noël Milpied, and Elif Hindié, Bordeaux University Hospital, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6780DOI Listing
July 2018

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.

Blood 2018 06 3;131(25):2856-2859. Epub 2018 May 3.

Department of Hematology, Centre Hospitalier Universitaire (CHU) Rennes, Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-03-841262DOI Listing
June 2018

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.

Br J Haematol 2018 04 20;181(1):124-125. Epub 2017 Jan 20.

Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14494DOI Listing
April 2018

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

J Clin Oncol 2017 Dec 4;35(35):3898-3905. Epub 2017 Oct 4.

Martin Dreyling, Ludwig Maximilians University of Munich, Munich; Georg Lenz, University Hospital Münster, Münster; Marius Giurescu, Karl Köchert, Henrik Seidel, and Florian Hiemeyer, Bayer AG, Berlin, Germany; Armando Santoro, Humanitas Clinical and Research Center, Rozzano; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Luigina Mollica, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; George A. Follows, Addenbrooke's Hospital, Cambridge, United Kingdom; Won Seog Kim, Samsung Medical Center, Seoul, South Korea; Arnon Nagler, Tel Aviv University, Tel HaShomer, Israel; Panayiotis Panayiotidis, National and Kapodistrian University of Athens, Athens, Greece; Judit Demeter, Semmelweis University, Budapest, Hungary; Muhit Özcan, Ankara University School of Medicine, Ankara, Turkey; Marina Kosinova, Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation; Krimo Bouabdallah, University Hospital of Bordeaux, Pessac; Franck Morschhauser, Hôpital Claude Huriez, Lille, France; Don A. Stevens, Norton Cancer Institute, Louisville, KY; David Trevarthen, Comprehensive Cancer Care and Research Institute of Colorado, Englewood, CO; and Lisa Cupit, Li Liu, Carol Peña, Shuxin Yin, Jose Garcia-Vargas, and Barrett H. Childs, Bayer HealthCare Pharmaceuticals, Whippany, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.4648DOI Listing
December 2017

[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2017 Dec 22;104(12S):S131-S135. Epub 2017 Nov 22.

Universitätsklinikum Aachen, Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Aachen, Allemagne; Institut de cancérologie Lucien-Neuwirth, département d'hématologie clinique, Saint-Priest-en-Jarez, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.10.018DOI Listing
December 2017

Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

Eur J Nucl Med Mol Imaging 2017 10;44(11):1937-1939

Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-017-3773-6DOI Listing
October 2017

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

N Engl J Med 2017 09;377(13):1250-1260

From Service d'Hématologie Clinique (S.L.G., T.G.), Service d'Anatomopathologie (A.M.), and Service d'Hématologie Biologique (M.C.B.), Hôtel-Dieu Centre Hospitalier Universitaire (CHU) de Nantes, and Centre de Recherche en Cancérologie et Immunologie (S.L.G., M.C.B.) and Faculté de Médecine (S.L.G.), Université de Nantes, Nantes, Hemato-Oncologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Université Diderot Sorbonne Paris-Cité (C.T.), Université Descartes (C.T.), Département d'Hématologie, Faculté de Médecine, Université Paris-Sud (V.R.), Département d'Anatomopathologie (D.C.) and Département d'Hématologie (O.H.), Necker Hospital, APHP, Sorbonne Paris-Cité, and INSERM Unité 1163 et Centre National de la Recherche Scientifique (CNRS) Équipe de Recherche Labellisée 8654, Imagine Institute (O.H.), Paris, Département d'Hématologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse (L.O.), Service d'Hématologie Clinique et Thérapie Cellulaire, CHU de Bordeaux, Bordeaux (K.B.), Service d'Hématologie et Thérapie Cellulaire, CHU de Tours, Tours (C.D.), Service d'Hématologie, CHU d'Amiens, Amiens (G.D.), INSERM, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif (V.R.), Département d'Hématologie, CHU de Nancy, Nancy (P.F.), INSERM Unité 954, Vandoeuvre (P.F.), Service d'Hématologie Clinique, CHU de Dijon, and INSERM Unité Mixte de Recherche 1231, Dijon (O.C.), Service d'Hématologie, Centre Hospitalier d'Avignon, Avignon (H.Z.), Lymphoid Malignancies Unit, Hôpital Henri Mondor, APHP, Créteil (C.H.), Service d'Hématologie du Centre Hospitalier de Vendée, La Roche-sur-Yon (H.M.), Service Hématologie Clinique (R.H.) and Département d'Hématologie (T.L.), CHU de Rennes, INSERM Unité 917 (R.H.), and INSERM Unité 1236 (T.L.), Rennes, Département d'Hematology, Centre Henri-Becquerel et Université de Normandie Unité 1245, Rouen (F.J., H.T.), Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, CHU de Clermont-Ferrand et Université Clermont Auvergne, Clermont-Ferrand (O.T.), Service d'Hématologie, Clinique Victor Hugo, Le Mans (K.L.D.), Department of Hematology, Université de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, and CHU de Lille, Lille (F.M.), Département d'Hématologie Clinique, CHU de Montpellier, CNRS UMR 5235, Montpellier (G.C.), Service d'Oncologie et d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg (L.-M.F.), INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble Alpes (M.C., R.G.), Institute for Advanced Biosciences (M.C.), and Laboratoire de Génétique Onco-hématologie (M.C.) and Faculté de Médecine (R.G.), CHU de Grenoble Alpes, Grenoble, Service d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite (G.S.), and Université Claude Bernard Lyon 1 and Cancer Research Center of Lyon, INSERM 1052 CNRS 5286 Lyon, Lyon (G.S.) - all in France; and Département d'Hématologie, Cliniques Universitaires Saint-Luc-Université Catholique de Louvain, Brussels (E.V.D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1701769DOI Listing
September 2017

Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.

Eur J Nucl Med Mol Imaging 2017 08;44(8):1254-1257

Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-017-3714-4DOI Listing
August 2017

Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.

Br J Haematol 2016 Nov 19;175(4):652-660. Epub 2016 Aug 19.

Department of Nuclear Medicine, Hôpital Haut-Lévêque, University Hospital of Bordeaux, Pessac, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14292DOI Listing
November 2016

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.

Blood 2016 08 23;128(8):1081-92. Epub 2016 Jun 23.

Pôle Biologie and INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-662783DOI Listing
August 2016

Bendamustine is effective in T-cell prolymphocytic leukaemia.

Br J Haematol 2015 Mar 15;168(6):916-9. Epub 2014 Oct 15.

Service des Maladies du Sang, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13175DOI Listing
March 2015

Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms.

Eur J Cancer 2014 Jan 14;50(2):418-24. Epub 2013 Nov 14.

INSERM U916, Bordeaux, France; Department of Medical Biology, Institut Bergonié, Bordeaux, France; Université Bordeaux Segalen, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.10.012DOI Listing
January 2014

Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.

Curr Opin Oncol 2013 Mar;25 Suppl 2:S1-12

Service des Maladies du Sang, Hôpital Haut-Lévêque, Pessac, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835de8eeDOI Listing
March 2013

[An update on recent developments in non-Hodgkin's lymphoma].

Bull Cancer 2007 Jan;94(1):43-52

Service des maladies du sang, Hôpital Haut-Lévèque, 33604 Pessac.

View Article

Download full-text PDF

Source
January 2007